Is it time to say “shorter, safer, and smarter”?—interpreting early toxicity data from the PACE-C non-inferiority trial

Key Points

• Early toxicity data suggest improved safety and efficacy outcomes in the PACE-C trial.
• Non-inferiority trial revealed key insights into treatment risks with a focus on adverse effects.
• Assessment involved analyzing initial toxicity results to guide safer treatment protocols.
• Findings imply a need for updated treatment guidelines to balance safety and effectiveness.